1 min read
Selexis SA to Address Recombinant Protein Expression Bottlenecks at PEPTALK 2014
Selexis CSO to Present Data on the Recently Launched SURE CHO-Mplus™ Libraries
Geneva, Switzerland December 17, 2013 –...
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2022 Selexis SA. All Rights Reserved.
